Consolidated Condensed Statements of Cash Flows (USD $) In Millions, unless otherwise specified	9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Cash flows from operating activities:
Net earnings (loss)	$ 3,699	$ (5,796)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation and amortization	3,491	3,894
Impairment of goodwill and purchased intangible assets		9,188
Stock-based compensation expense	398	494
Provision for doubtful accounts-accounts and financing receivables	43	60
Provision for inventory	222	194
Restructuring charges	619	1,888
Deferred taxes on earnings	542	(690)
Excess tax benefit from stock-based compensation	(1)	(12)
Other, net	343	330
Changes in operating assets and liabilities:
Accounts and financing receivables	2,640	2,435
Inventory	(445)	(2)
Accounts payable	(70)	(2,196)
Taxes on earnings	(520)	(40)
Restructuring	(644)	(472)
Other assets and liabilities	(1,525)	(2,763)
Net cash provided by operating activities	8,792	6,512
Cash flows from investing activities:
Investment in property, plant and equipment	(2,280)	(2,833)
Proceeds from sale of property, plant and equipment	507	321
Purchases of available-for-sale securities and other investments	(793)	(793)
Maturities and sales of available-for-sale securities and other investments	874	516
Payments made in connection with business acquisitions, net of cash acquired	(167)	(141)
Proceeds from business divestiture, net		87
Net cash used in investing activities	(1,859)	(2,843)
Cash flows from financing activities:
Repayment of commercial paper and notes payable, net	(170)	(2,553)
Issuance of long-term debt	254	5,100
Payment of long-term debt	(3,473)	(3,222)
Issuance of common stock under employee stock plans	279	710
Repurchase of common stock	(1,053)	(1,495)
Excess tax benefit from stock-based compensation	1	12
Cash dividends paid	(821)	(755)
Net cash used in financing activities	(4,983)	(2,203)
Increase in cash and cash equivalents	1,950	1,466
Cash and cash equivalents at beginning of period	11,301	8,043
Cash and cash equivalents at end of period	$ 13,251	$ 9,509